This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, announced the publication of an article by Bernstein et al entitled, “Cholesteryl Ester Storage Disease: Review of the Findings in 135 Reported Patients with an Under-Diagnosed Disease” in the online version and an upcoming print edition of the Journal of Hepatology.

“We performed the most comprehensive review and analysis of late onset LAL Deficiency, or cholesteryl ester storage disease, cases found in the literature,” said Donna Bernstein, MS, CGC, the lead author and a genetic counselor in the Division of Medical Genetics, Director of the Lysosomal Storage Disease Program at North Shore-Long Island Jewish Health System. “Based on this review, we found that the abnormal fat accumulation in liver cells, adrenal glands, intestines, and macrophages due to LAL Deficiency can lead to cirrhosis, high LDL, low HDL, accelerated atherosclerosis, and early demise,” said Robert J. Desnick, MD, PhD, senior author of the study and Dean for Genetic and Genomic Medicine, Professor and Chairman Emeritus, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai Hospital. “LAL Deficiency may present in infancy, childhood, or adulthood but because the diagnosis is challenging, it is likely that many adult CESD patients, in particular, are being misclassified as having NAFLD, NASH, unexplained liver disease, familial hypercholesterolemia, or remain undiagnosed before succumbing to liver failure, stroke, myocardial infarction, or sudden death.”

About the late onset LAL Deficiency literature review

The literature review included 135 cases found in the published scientific literature for whom clinical information was reported. The median age of earliest symptom onset and/or diagnosis of the cases reviewed was 5 years (range from birth to 68 years), with greater than 80% experiencing symptom and/or disease onset by 12 years of age. The review excluded patients diagnosed with early onset LAL Deficiency (or Wolman disease) who died in the first year of life.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs